Complement factor H variant Y402H is not a risk factor for preeclampsia in the finnish population

Hypertension in Pregnancy

Volumn 27, Issue 4, 2008, Pages 328-336

  Kaare, M ^a   Seitsonen, S ^b   Jarvela I ^b,c   Meri, S ^b   Laivuori, H ^b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Association test; Complement factor H; Polymorphism; Preeclampsia; Vascular disorder

Indexed keywords

COMPLEMENT FACTOR H; DNA;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PREGNANCY; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ALLELES; COMPLEMENT FACTOR H; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FINLAND; GENE FREQUENCY; GENOTYPE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RETROSPECTIVE STUDIES;

EID: 56049095980     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.1080/10641950801955691     Document Type: Article

References (35)

1. Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, Varner MW. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001; 344:867-872.
2. Skjaerven R, Vatten LJ, Wilcox AJ, Ronning T, Irgens LM and Lie RT. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ 2005; 331:877.
3. Duckitt K and Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330:565.
4. Irgens HU, Reisater L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. Pre-eclampsia and cardiovascular disease later in life: who is at risk? BMJ 2001; 323:1213-1217.
5. Redman CWG and Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - A review. Placenta 2003; 24:S21-S27.
6. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180:499-506.
7. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
8. Oksjoki R, Kovanen P, Pentikainen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003; 14:477-482.
9. Jozsi M, Manuelian T, Heinen S, Oppermann M, Zipfel PF. Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology. Histol Histopathol 2004; 19:251-258.
10. Zipfel PF, Heinen S, Jozsi M and Skerka C. Complement and diseases: Defective alternative pathway control results in kidney and eye diseases. Molec Immunol 2006; 43:97-106.
11. Johansen KA, Williams JH, Stark JM. Acute-phase C56-forming ability and concentrations of complement components in normotensive and hypertensive pregnancies. Br J Obstet Gynaecol 1981; 88:504-512.
12. Haeger M, Bengtson A, Karlsson K., Heideman M. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid. Obstet Gynecol 1989; 73:551-556.
13. Edwards AO, Ritter RIII, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308:421-424.
14. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308:419-421.
15. Klein RJ, Zeiss C, Chew EY, Tsai J, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:385-389.
16. Seitsonen S, Lemmela S, Holopainen J, Tommila P, Ranta P, Kotamies A., Moilanen J, Palosaari T, Kaarniranta K, Meri S, Immonen I, Jarvela I. Analysis of variants in the complement factor H, the elongation of very long chain fatty acids-like 4 and the hemicentin 1 genes of age-related macular degeneration in the Finnish population. Molecular Vision 2006; 12:796-801.
17. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134:411-431.
18. Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, de Maat MP, Boekhoorn SS, Vingerling JR, Hofman A, Oostra BA Uitterlinden AG, Stijnen T, van Duijn CM, de Jong PT. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006; 296:301-309.
19. Kardys I, Klaver CCW, Despriet DDG, Bergen AAB, Uitterlinden AG, Hofman A, Oostra BA, Van Duijn CM, de Jong PTVM, Witteman JCM. A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: The Rotterdam study. J Am Coll Cardiol 2006; 47:1568-1575.
20. Goverdhan SV, Lotery AJ, Cree AJ, Ye S. Complement factor H Y402H gene polymorphism in coronary artery disease and atherosclerosis. Atherosclerosis 2006; 188:213-214.
21. Zee, R.Y.L., Diehl, K.A. and Ridker, P.M. Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: A nested case-control study. Atherosclerosis 2006; 187:332-335.
22. Jokiranta TS, Cheng Z, Seeberger H, Jozsi M, Heinen S, Noris M, Remuzzi G, Ormsby R, Gordon DL, Meri S, Hellwage J, Zipfel PF. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol 2005; 167:1173-1181.
23. Jokiranta TS, Jaakola VP, Lehtinen MJ, Parepalo M, Meri S, Goldman A. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome EMBO J 2006; 25:1784-1794.
24. Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HPH, Remuzzi G, Zipfel PF (2003) Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111:1181-1190.
25. nd ed. Stamford, CT: Appleton & Lange, 1999:231-262.
26. Laivuori H, Kaaja R, Ylikorkala O, Hiltunen T, Kontula, K. 677 C>T polymorphism of the methylenetetrahydrofolate reductase gene and preeclampsia. Obstet Gynecol 2000; 96:277-280.
27. Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, Vera M, Lopez-Trascasa M, Rodriguez de Cordoba S, Sanchez-Corral P. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001; 68:478-84.
28. Giannakis E, Jokiranta TS, Male DA, Ranganathan S, Ormsby RJ, Fischetti VA, Mold C, Gordon, DL. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol 2003; 33:962-969.
29. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999; 163:3957-3962.
30. Egerman RS and Sibai BM. Imitators of preeclampsia and eclampsia. Clin Obstet Gynecol 1999; 42:551-562.
31. Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol 2007; 109:956-966.
32. Iannuzzi M, Siconolfi P, D'Angelillo A, Capuano M, Tufano L, Macri, M. A post-partum hemolytic-uremic-like-syndrome in a patient with pre-eclampsia: Description of a clinical case. Transfusion and Apheresis. Science 2006; 34:11-14.
33. Ness RB and Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. Am J Obstet Gynecol 1996; 175:1365-1370.
34. Redman CW and Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308:1592-1594.
35. Girardi G, Bulla R, Salmon JE, Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol 2006; 43:68-77.